```
=> d his

     (FILE 'HOME' ENTERED AT 15:53:30 ON 11 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 15:53:40 ON 11 MAR 2005
L1               STRUCTURE UPLOADED
L2               STRUCTURE UPLOADED
L3             0 S L1 OR L2
L4             0 S L1
L5             8 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:55:21 ON 11 MAR 2005
L6             1 S L5

     FILE 'REGISTRY' ENTERED AT 15:55:38 ON 11 MAR 2005
L7             0 S L2
L8             0 S L2 FULL

     FILE 'CAPLUS' ENTERED AT 15:56:37 ON 11 MAR 2005

=> d que l5 stat
L1               STR
```



1

G1 O,S

G2 H,Ak

G3 COOH,CN,[@1]

```
Structure attributes must be viewed using STN Express query preparation.
L5             8 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 365479 ITERATIONS                          8 ANSWERS
SEARCH TIME: 00.00.04


=> d l6 bib abs hitstr
```

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:868433 CAPLUS
DN 136:20062
TI Preparation of heterocyclic compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.
IN Kuwabara, Kenji; Aoki, Tomiyoshi
PA Nippon Shinyaku Co., Ltd., Japan
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062
AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic heterocyclic group; Het is a divalent aromatic heterocyclic group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.
IT **377731-39-0P 377731-44-7P 377731-64-1P 377732-13-3P 377732-15-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)
RN 377731-39-0 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 377731-44-7 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 377731-64-1 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 377732-13-3 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]phenyl]methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 377732-15-5 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]phenyl]methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **377733-07-8 377733-11-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)
RN 377733-07-8 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 377733-11-4 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]phenyl]methyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **377732-58-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)
RN 377732-58-6 CAPLUS
CN Oxazole, 4-[[3-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]phenyl]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l8
L9            0 L8

=> d que l9 stat
L2               STR
```



1

G1 O,S

G2 H,Ak

G3 COOH,CN,[@1]

```
Structure attributes must be viewed using STN Express query preparation.
L8             0 SEA FILE=REGISTRY SSS FUL L2
L9             0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8


=> => d que l13 stat
L10           31 SEA FILE=CAPLUS ABB=ON  PLU=ON  "KUWABARA KENJI"/AU
L11            7 SEA FILE=CAPLUS ABB=ON  PLU=ON  "AOKI TOMIYOSHI"/AU
L12           35 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 OR L11
L13            3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 AND (OXAZOLE OR THIAZOLE
                 OR HETEROCYCLIC)


=> d 1-3 bib abs
```

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:868433 CAPLUS
DN 136:20062
TI Preparation of **heterocyclic** compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.
IN **Kuwabara, Kenji; Aoki, Tomiyoshi**
PA Nippon Shinyaku Co., Ltd., Japan
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062
AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic **heterocyclic** group; Het is a divalent aromatic **heterocyclic** group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:453023 CAPLUS
DN 135:46207
TI Preparation of **heterocyclic** derivatives as anticancer agents
IN Suzuki, Toshiyuki; **Aoki, Tomiyoshi**
PA Nippon Shinyaku Co., Ltd., Japan
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001044195	A1	20010621	WO 2000-JP8781	20001213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393358	AA	20010621	CA 2000-2393358	20001213
AU 2001018873	A5	20010625	AU 2001-18873	20001213
EP 1238974	A1	20020911	EP 2000-981657	20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003022884	A1	20030130	US 2002-149622	20020612
US 6787546	B2	20040907		
PRAI JP 1999-354101	A	19991214		
JP 2000-202393	A	20000704		
WO 2000-JP8781	W	20001213		

OS MARPAT 135:46207
AB The title compds. ABDE [A is heteroaryl or an oxide thereof; B is ethenylene; D is optionally substituted phenylene; and E is a group of general formula N(COR)SO2G (G is optionally substituted phenyl; and R is heteroaryl, heteroarylmethyl), etc.] are prepared A course of 5 injections of (E)-4-(2-(2-(N-(4-methoxybenzenesulfonyl)-N-(4-(2-pyridyl)piperazino)acetylamino)phenyl)ethenyl)pyridine 1-oxide dihydrochloride at 50 mg/kg i.v. gave 80% inhibition of tumor in mice. Formulations are given.
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:448300 CAPLUS
DN 125:132061
TI The effect of SM-8849 on experimental arthritis in mice
AU Nagai, Hiroichi; Takaoka, Yuko; **Kuwabara, Kenji**; Kamada, Hiroyuki; Kitagaki, Kunihiko
CS Department Pharmacology, Gifu Pharmaceutical University, Gifu, 205, Japan
SO Pharmacology (1996), 52(6), 377-386
CODEN: PHMGBN; ISSN: 0031-7012
PB Karger
DT Journal
LA English
AB The effect of a novel **thiazole** derivative, SM-8849, on exptl. arthritis in mice was studied and compared to that of prednisolone. SM-8849 and prednisolone reduced the incidence and severity of type II collagen-induced arthritis in mice, as assayed by clin. observation and histopathol. studies. Although both agents inhibited type II collagen-induced delayed type hypersensitivity (DTH) in arthritic mice, SM-8849 did not affect the production of humoral antibodies to type II collagen. To examine the inhibitory mechanism of SM-8849, the effects on T cell-dependent allergic inflammation were studied. SM-8849 clearly inhibited T cell-dependent reactions including staphylococcal enterotoxin B (SEB)-induced arthritis, SEB-induced CD25 expression on T cells and sheep red blood cell (SRBC)-induced DTH reaction. SM-8849, however, had no effect on the production of humoral antibody forming cells in the spleen of mice immunized with SRBC. These results indicate that inhibition of type II collagen-induced arthritis by SM-8849 is mainly due to the inactivation of T cells that are related to DTH reaction.

```
=> => fil capl
FILE 'CAPLUS' ENTERED AT 16:07:19 ON 11 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 11 Mar 2005  VOL 142 ISS 12
FILE LAST UPDATED: 10 Mar 2005  (20050310/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l18
L19           1 L18

=> d que l19 stat
L2                STR
```



1

G1 O,S

G2 H,Ak

G3 COOH,CN,[@1]

```
Structure attributes must be viewed using STN Express query preparation.
L16       638116 SEA FILE=REGISTRY ABB=ON  PLU=ON  16.299/RID
L18            3 SEA FILE=REGISTRY SUB=L16 SSS FUL L2
L19            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18

=> d bib abs hitstr
```

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:868433 CAPLUS
DN 136:20062
TI Preparation of heterocyclic compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.
IN Kuwabara, Kenji; Aoki, Tomiyoshi
PA Nippon Shinyaku Co., Ltd., Japan
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062
AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic heterocyclic group; Het is a divalent aromatic heterocyclic group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.
IT **377732-03-1P 377732-35-9P 377732-36-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)
RN 377732-03-1 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]butyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 377732-35-9 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]butyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 377732-36-0 CAPLUS
CN 1,3-Dioxane-2-carboxylic acid, 5-[4-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-thiazolyl]butyl]-2-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT